Ivana Jovcevska

List of Publications by Year in descending order

24 papers	1,059 citations	623734 14 h-index	677142 22 g-index
24 all docs	24 docs citations	24 times ranked	1688 citing authors

#	Article	IF	Citations
1	The Therapeutic Potential of Nanobodies. BioDrugs, 2020, 34, 11-26.	4.6	435
2	Glioma and glioblastoma - how much do we (not) know?. Molecular and Clinical Oncology, 2013, 1, 935-941.	1.0	154
3	Nanotechnology Meets Oncology: Nanomaterials in Brain Cancer Research, Diagnosis and Therapy. Materials, 2019, 12, 1588.	2.9	95
4	Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates. Oncotarget, 2017, 8, 44141-44158.	1.8	44
5	Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma. Molecules, 2020, 25, 490.	3.8	31
6	Sequencing the next generation of glioblastomas. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 264-282.	6.1	27
7	TRIM28 and Î²-Actin Identified via Nanobody-Based Reverse Proteomics Approach as Possible Human Glioblastoma Biomarkers. PLoS ONE, 2014, 9, e113688.	2.5	26
8	Coding of Glioblastoma Progression and Therapy Resistance through Long Noncoding RNAs. Cancers, 2020, 12, 1842.	3.7	26
9	Next Generation Sequencing and Machine Learning Technologies Are Painting the Epigenetic Portrait of Glioblastoma. Frontiers in Oncology, 2020, 10, 798.	2.8	26
10	Analysis of miR-9-5p, miR-124-3p, miR-21-5p, miR-138-5p, and miR-1-3p in Glioblastoma Cell Lines and Extracellular Vesicles. International Journal of Molecular Sciences, 2020, 21, 8491.	4.1	25
11	Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091530.	3.2	25
12	Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting. Oncotarget, 2018, 9, 17282-17299.	1.8	21
13	Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy: A systematic review. Critical Reviews in Oncology/Hematology, 2021, 160, 103283.	4.4	17
14	High FREM2 Gene and Protein Expression Are Associated with Favorable Prognosis of IDH-WT Glioblastomas. Cancers, 2019, 11, 1060.	3.7	16
15	TRIM28 Selective Nanobody Reduces Glioblastoma Stem Cell Invasion. Molecules, 2021, 26, 5141.	3.8	16
16	Genetic secrets of long-term glioblastoma survivors. Bosnian Journal of Basic Medical Sciences, 2019, 19, 116-124.	1.0	15
17	Large-Scale Transcriptomics-Driven Approach Revealed Overexpression of CRNDE as a Poor Survival Prognosis Biomarker in Glioblastoma. Cancers, 2021, 13, 3419.	3.7	14
18	Current Technologies for RNA-Directed Liquid Diagnostics. Cancers, 2021, 13, 5060.	3.7	14

#	Article	IF	Citations
19	Meta-Analysis and Experimental Validation Identified FREM2 and SPRY1 as New Glioblastoma Marker Candidates. International Journal of Molecular Sciences, 2018, 19, 1369.	4.1	11
20	Algorithmically Deduced FREM2 Molecular Pathway Is a Potent Grade and Survival Biomarker of Human Gliomas. Cancers, 2021, 13, 4117.	3.7	9
21	Neuroepigenetics of psychiatric disorders: Focus on lncRNA. Neurochemistry International, 2021, 149, 105140.	3.8	8
22	Dynamic Intercell Communication between Glioblastoma and Microenvironment through Extracellular Vesicles. Biomedicines, 2022, 10, 151.	3.2	4
23	OligoPrime: An Information System for Oligonucleotide Management. Biomedical Engineering and Computational Biology, 2021, 12, 117959722110419.	2.0	0
24	Biological nanodrugs for brain targeting. , 2022, , 797-820.		0